The Manufacturers Life Insurance Company Purchases Shares of 10,688 ANI Pharmaceuticals, Inc. $ANIP

The Manufacturers Life Insurance Company acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,688 shares of the specialty pharmaceutical company’s stock, valued at approximately $885,000.

Several other large investors have also recently modified their holdings of ANIP. KBC Group NV purchased a new stake in ANI Pharmaceuticals during the 1st quarter valued at about $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. lifted its position in ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, State of Wyoming bought a new position in shares of ANI Pharmaceuticals in the second quarter worth approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total value of $401,220.00. Following the completion of the transaction, the chief executive officer directly owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Carey sold 3,313 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the sale, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,925 shares of company stock valued at $1,890,145 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ANIP. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Canaccord Genuity Group dropped their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $71.23 on Friday. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of 15.35 and a beta of 0.45. The stock has a fifty day moving average of $78.62 and a 200 day moving average of $78.44. ANI Pharmaceuticals, Inc. has a 52 week low of $70.15 and a 52 week high of $99.50. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period in the previous year, the firm earned $1.80 EPS. The company’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.